Cardiac secretion of adrenomedullin in human heart failure

Michihisa Jougasaki, Richard J. Rodeheffer, Margaret May Redfield, Kazuhiro Yamamoto, Chi Ming Wei, Linda J. McKinley, John C Jr. Burnett

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

Adrenomedullin (ADM) is a newly discovered endogenous vasorelaxing and natriuretic peptide. Recently, we have reported that plasma ADM is increased in severe congestive heart failure (CHF) in humans and that increased immunohistochemical staining is observed in the failing human ventricular myocardium. The present study was designed to test the hypothesis that the failing human ventricle secretes ADM and that circulating ADM progressively increases with the severity of clinical CHF. Plasma ADM was significantly increased in human CHF (39.8±3.6 pg/ml, P < 0.001 vs. normal) as compared with normal subjects (14.4±2.7 pg/ml). Plasma ADM was increased in mild CHF (NYHA class II, 30.1±3.4 pg/ml, P < 0.01 vs. normal), moderate CHF (NYHA class III, 31.5±3.0 pg/ml, P < 0.01 vs. normal), and severe CHF (NYHA class IV, 66.1±9.4 pg/ml, P < 0.001 vs. normal). In 13 patients with CHF in whom plasma samples were obtained from aorta (AO), coronary sinus (CS) and anterior interventricular vein (AIV), there was a significant step-up in plasma ADM between AO and AIV (50.6±9.3 pg/ml and 62.1±11.1 pg/ml, respectively, P < 0.01) and between AO and CS (50.6±9.3 pg/ml and 58.6±11.4 pg/ml, respectively, P < 0.05). The current study demonstrates that the failing human heart secretes ADM in human CHF suggesting contribution to the increase in plasma ADM, and indicates for the first time an additional endocrine system of cardiac origin which is activated in human CHF and may function in cardiorenal regulation.

Original languageEnglish (US)
Pages (from-to)2370-2376
Number of pages7
JournalJournal of Clinical Investigation
Volume97
Issue number10
StatePublished - May 15 1996

Fingerprint

Adrenomedullin
Heart Failure
Aorta
Coronary Sinus
Veins
human ADM protein
Natriuretic Peptides
Endocrine System
Myocardium
Staining and Labeling

Keywords

  • heart failure, congestive
  • heart ventricle
  • hormones
  • myocardium
  • peptides

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jougasaki, M., Rodeheffer, R. J., Redfield, M. M., Yamamoto, K., Wei, C. M., McKinley, L. J., & Burnett, J. C. J. (1996). Cardiac secretion of adrenomedullin in human heart failure. Journal of Clinical Investigation, 97(10), 2370-2376.

Cardiac secretion of adrenomedullin in human heart failure. / Jougasaki, Michihisa; Rodeheffer, Richard J.; Redfield, Margaret May; Yamamoto, Kazuhiro; Wei, Chi Ming; McKinley, Linda J.; Burnett, John C Jr.

In: Journal of Clinical Investigation, Vol. 97, No. 10, 15.05.1996, p. 2370-2376.

Research output: Contribution to journalArticle

Jougasaki, M, Rodeheffer, RJ, Redfield, MM, Yamamoto, K, Wei, CM, McKinley, LJ & Burnett, JCJ 1996, 'Cardiac secretion of adrenomedullin in human heart failure', Journal of Clinical Investigation, vol. 97, no. 10, pp. 2370-2376.
Jougasaki M, Rodeheffer RJ, Redfield MM, Yamamoto K, Wei CM, McKinley LJ et al. Cardiac secretion of adrenomedullin in human heart failure. Journal of Clinical Investigation. 1996 May 15;97(10):2370-2376.
Jougasaki, Michihisa ; Rodeheffer, Richard J. ; Redfield, Margaret May ; Yamamoto, Kazuhiro ; Wei, Chi Ming ; McKinley, Linda J. ; Burnett, John C Jr. / Cardiac secretion of adrenomedullin in human heart failure. In: Journal of Clinical Investigation. 1996 ; Vol. 97, No. 10. pp. 2370-2376.
@article{c1e4fb7e3ba541a09c48fe78c6b8a7b3,
title = "Cardiac secretion of adrenomedullin in human heart failure",
abstract = "Adrenomedullin (ADM) is a newly discovered endogenous vasorelaxing and natriuretic peptide. Recently, we have reported that plasma ADM is increased in severe congestive heart failure (CHF) in humans and that increased immunohistochemical staining is observed in the failing human ventricular myocardium. The present study was designed to test the hypothesis that the failing human ventricle secretes ADM and that circulating ADM progressively increases with the severity of clinical CHF. Plasma ADM was significantly increased in human CHF (39.8±3.6 pg/ml, P < 0.001 vs. normal) as compared with normal subjects (14.4±2.7 pg/ml). Plasma ADM was increased in mild CHF (NYHA class II, 30.1±3.4 pg/ml, P < 0.01 vs. normal), moderate CHF (NYHA class III, 31.5±3.0 pg/ml, P < 0.01 vs. normal), and severe CHF (NYHA class IV, 66.1±9.4 pg/ml, P < 0.001 vs. normal). In 13 patients with CHF in whom plasma samples were obtained from aorta (AO), coronary sinus (CS) and anterior interventricular vein (AIV), there was a significant step-up in plasma ADM between AO and AIV (50.6±9.3 pg/ml and 62.1±11.1 pg/ml, respectively, P < 0.01) and between AO and CS (50.6±9.3 pg/ml and 58.6±11.4 pg/ml, respectively, P < 0.05). The current study demonstrates that the failing human heart secretes ADM in human CHF suggesting contribution to the increase in plasma ADM, and indicates for the first time an additional endocrine system of cardiac origin which is activated in human CHF and may function in cardiorenal regulation.",
keywords = "heart failure, congestive, heart ventricle, hormones, myocardium, peptides",
author = "Michihisa Jougasaki and Rodeheffer, {Richard J.} and Redfield, {Margaret May} and Kazuhiro Yamamoto and Wei, {Chi Ming} and McKinley, {Linda J.} and Burnett, {John C Jr.}",
year = "1996",
month = "5",
day = "15",
language = "English (US)",
volume = "97",
pages = "2370--2376",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "10",

}

TY - JOUR

T1 - Cardiac secretion of adrenomedullin in human heart failure

AU - Jougasaki, Michihisa

AU - Rodeheffer, Richard J.

AU - Redfield, Margaret May

AU - Yamamoto, Kazuhiro

AU - Wei, Chi Ming

AU - McKinley, Linda J.

AU - Burnett, John C Jr.

PY - 1996/5/15

Y1 - 1996/5/15

N2 - Adrenomedullin (ADM) is a newly discovered endogenous vasorelaxing and natriuretic peptide. Recently, we have reported that plasma ADM is increased in severe congestive heart failure (CHF) in humans and that increased immunohistochemical staining is observed in the failing human ventricular myocardium. The present study was designed to test the hypothesis that the failing human ventricle secretes ADM and that circulating ADM progressively increases with the severity of clinical CHF. Plasma ADM was significantly increased in human CHF (39.8±3.6 pg/ml, P < 0.001 vs. normal) as compared with normal subjects (14.4±2.7 pg/ml). Plasma ADM was increased in mild CHF (NYHA class II, 30.1±3.4 pg/ml, P < 0.01 vs. normal), moderate CHF (NYHA class III, 31.5±3.0 pg/ml, P < 0.01 vs. normal), and severe CHF (NYHA class IV, 66.1±9.4 pg/ml, P < 0.001 vs. normal). In 13 patients with CHF in whom plasma samples were obtained from aorta (AO), coronary sinus (CS) and anterior interventricular vein (AIV), there was a significant step-up in plasma ADM between AO and AIV (50.6±9.3 pg/ml and 62.1±11.1 pg/ml, respectively, P < 0.01) and between AO and CS (50.6±9.3 pg/ml and 58.6±11.4 pg/ml, respectively, P < 0.05). The current study demonstrates that the failing human heart secretes ADM in human CHF suggesting contribution to the increase in plasma ADM, and indicates for the first time an additional endocrine system of cardiac origin which is activated in human CHF and may function in cardiorenal regulation.

AB - Adrenomedullin (ADM) is a newly discovered endogenous vasorelaxing and natriuretic peptide. Recently, we have reported that plasma ADM is increased in severe congestive heart failure (CHF) in humans and that increased immunohistochemical staining is observed in the failing human ventricular myocardium. The present study was designed to test the hypothesis that the failing human ventricle secretes ADM and that circulating ADM progressively increases with the severity of clinical CHF. Plasma ADM was significantly increased in human CHF (39.8±3.6 pg/ml, P < 0.001 vs. normal) as compared with normal subjects (14.4±2.7 pg/ml). Plasma ADM was increased in mild CHF (NYHA class II, 30.1±3.4 pg/ml, P < 0.01 vs. normal), moderate CHF (NYHA class III, 31.5±3.0 pg/ml, P < 0.01 vs. normal), and severe CHF (NYHA class IV, 66.1±9.4 pg/ml, P < 0.001 vs. normal). In 13 patients with CHF in whom plasma samples were obtained from aorta (AO), coronary sinus (CS) and anterior interventricular vein (AIV), there was a significant step-up in plasma ADM between AO and AIV (50.6±9.3 pg/ml and 62.1±11.1 pg/ml, respectively, P < 0.01) and between AO and CS (50.6±9.3 pg/ml and 58.6±11.4 pg/ml, respectively, P < 0.05). The current study demonstrates that the failing human heart secretes ADM in human CHF suggesting contribution to the increase in plasma ADM, and indicates for the first time an additional endocrine system of cardiac origin which is activated in human CHF and may function in cardiorenal regulation.

KW - heart failure, congestive

KW - heart ventricle

KW - hormones

KW - myocardium

KW - peptides

UR - http://www.scopus.com/inward/record.url?scp=0029976990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029976990&partnerID=8YFLogxK

M3 - Article

C2 - 8636418

AN - SCOPUS:0029976990

VL - 97

SP - 2370

EP - 2376

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 10

ER -